

CURRICULUM VITAE

Michael Hauptmann

May 21, 2021

Personal Data

Date of birth August 25, 1969
Place of birth Limburg, Germany
Citizenship Germany
Work address Institute of Biostatistics and Registry Research
Medical School Brandenburg
Campus Neuruppin, O Building
Fehrbelliner Strasse 38, 16816 Neuruppin, Germany
Phone: +49-3391-39-14580, E-Mail: michael.hauptmann@mhb-fontane.de

Education

Ph.D., Department of Statistics, University of Dortmund, Germany, 1999
Dissertation “Analysis of exposure-time-response relationships using a spline weight function and its application in epidemiology” (Advisors: Siegfried Schach, Lothar Kreienbrock)
M.S., Department of Statistics, University of Dortmund, Germany, 1995
Thesis “Correction of errors in covariates of regression models using calibration data”

Professional Experience

Professor of Biostatistics and Registry Research, 2019–current
Head, Institute of Biostatistics and Registry Research, 2019–current
Director, Clinical Research Center, 2019–current
Brandenburg Medical School Theodor Fontane, Neuruppin, Germany
Head, Biostatistics Branch, 2011–2019
Investigator (tenured), 2006–2011
Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, Netherlands
Investigator (tenure-track), 2004–2006
Postdoctoral Fellow, 1999–2004
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, U.S.A.
Staff Scientist, 1998–1999
Predoctoral Fellow, 1995–1998
Institute of Epidemiology, GSF National Research Center for Environment and Health, Neuherberg, Germany (now: Helmholtz Zentrum München)

Editorial Positions and Professional Memberships

Member, German Commission on Radiological Protection (Strahlenschutzkommission), Committee “Radiation risk” (2020–current)

Member, Ad-hoc Commission Methods for Real World Data and Real World Evidence, Deutsches Netzwerk Versorgungsforschung (DNVF) [German Network for Health Services Research] (2020–current)

Member, Board of Advisors, Clinical Cancer Registry Berlin-Brandenburg (2020–current)

Member, International Commission on Radiological Protection (ICRP), Committee "Radiation effects" (2013–current)

Member (Statistical Consultant), Editorial Board, Cancer Epidemiology (2011–current)

Statistical Editor, Journal of the National Cancer Institute (2005–current)

Member, Board of Advisors, Dutch Cancer Society (2015–2021)

Member, Editorial Board, Journal of Clinical Oncology (2015–2020)

Member, Working Group of the IARC Monograph Volume 88 "Formaldehyde, 2-butoxyethanol and propylene glycol mono-t-butyl ether", Lyon, France (June 2004)

Member, International Biometric Society

Member, German Epidemiological Association

Honors and Fellowships

Young Investigators Travel Award, American Statistical Association Conference on Radiation & Health (2004)

Outstanding Research Paper by a Fellow Award, Division of Cancer Epidemiology and Genetics, National Cancer Institute, U.S. National Institutes of Health (2004)

Fellows Award for Research Excellence, U.S. National Institutes of Health (2003)

Technology Transfer Award, U.S. National Institutes of Health (2001)

Fellows Award for Research Excellence, U.S. National Institutes of Health (2000)

Travel Grant to visit the U.S. National Cancer Institute, German Academic Exchange Service (DAAD) (Winter 1997/98)

Study Grant, Konrad Adenauer Foundation (1991–1995)

Bibliography

Refereed Articles

1. Hoffmann F, Kaiser T, Apfelbacher C, Benz S, Bierbaum T, Dreinhöfer KE, **Hauptmann M**, Heidecke CD, Koller M, Kostuj T, Ortman O, Schmitt J, Schünemann H, Veit C, Hoffmann W, Klinkhammer-Schalke M. Versorgungsnahe Daten zur Evaluation von Interventionseffekten: Teil 2 des Manuals [Routine Practice Data for Evaluating Intervention Effects: Part 2 of the Manual]. *Gesundheitswesen* 2021. In press.
2. Dackus GM, Jozwiak K, Sonke GS, Van der Wall E, Van Diest PJ, Siesling S, **Hauptmann M** (joint senior author), Linn SC. Adjuvant aromatase inhibitors or tamoxifen following chemotherapy for perimenopausal breast cancer patients. *J Natl Cancer Inst.* In press.

3. Little MP, Pawel DJ, Abalo K, **Hauptmann M**. Methodological improvements to meta-analysis of low dose rate studies and derivation of Dose and Dose-rate Effectiveness Factors. *Radiat Environ Biophys*. In press.
4. Didczuneit-Sandhop B, Jozwiak K, Jolie K, Holdys J, **Hauptmann M**. Hearing loss among elderly people and access to hearing aids: a cross-sectional study from a rural area in Germany. *Eur Arch Otorhinolaryngol*. In press.
5. Van der Willik KD, Jozwiak K, **Hauptmann M**, Van de Velde EE, Compter A, Ruiters R, Stricker BH, Ikram A, Schagen SB. Change in cognition before and after non-central nervous system cancer diagnosis: a population-based cohort study. *Psychooncology*. In press.
6. Thierry-Chef I, Ferro G, Le Cornet L, Dabin J, Istad TS, Jahnen A, Lee C, Maccia C, Malchair F, Olerud HM, Harbron RW, Figuerola J, Hermen J, Moissonnier M, Bernier MO, Bosch de Basea M, Byrnes G, Cardis E, **Hauptmann M**, Journy N, Kesminiene A, Meulepas JM, Pokora R, Simon SL. Dose estimation for the European epidemiological study on pediatric computed tomography (EPI-CT). *Radiat Res*. In press.
7. Banys-Paluchowski M, Gasparri ML, De Boniface J, Gentilini O, Stickeler E, Hartmann S, Thill M, Rubio IT, Di Micco R, Bonci EA, Niinikoski L, Kontos M, Karadeniz Cakmak G, **Hauptmann M**, Peintinger F, Pinto D, Matrai Z, Murawa D, Kadayaprath G, Dostalek L, Nina H, Krivorotko P, Classe JM, Schlichting E, Appelgren M, Paluchowski P, Solbach C, Blohmer JU, Kühn T and the AXSANA study group. Surgical management of the axilla in clinically node-positive breast cancer patients who convert to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps and rationale for the AXSANA study of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). *Cancers* 2021; 13(7): 1565.
8. Graeser M, Feuerhake F, Gluz O, Volk V, **Hauptmann M**, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. *J Immunother Cancer* 2021; 9(5): e002198.
9. Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, **Hauptmann M**, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity: A Randomized Clinical Trial. *Otol Neurotol* 2021; 42(5): 678–685.
10. Dackus GM, Jozwiak K, Van der Wall E, Van Diest PJ, **Hauptmann M**, Siesling S, Sonke GS, Linn SC. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. *Breast Cancer Res Treat* 2021; 185(3): 817–830.
11. Jacobse JN, Schaapveld M, Boekel NB, Hoening MJ, Jager A, Baaijens A, **Hauptmann M**, Russel NS, Rutgers EJ, Sonke GS, Aleman BM, Van Leeuwen FE. Risk of heart failure after systemic treatment for early breast cancer; results of a cohort study. *Breast Cancer Res Treat* 2021; 185(1): 205–214.
12. Terra L, Hoening MJ, Heemskerk-Gerritsen BA, Van Beurden M, Roeters van Lennep JE, Van Doorn HC, De Hullu JA, Van Dorst EB, Mom CH, Mourits MJ, Slangen BF, Gaarenstroom KN, Zillikens MC, Leiner T, Van der Kolk L, Collee JM, Wevers MR, Ausems MG, Kenter GG, Meijers H, Oosterwijk JC, Van Asperen CJ, Gomez Garcia EB, Rookus MA, **Hauptmann M**, Bleiker EM, Schagen SB, Aaronson NK, Maas AH, Van Leeuwen FE. Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: rationale and design of the HARMONY study. *JMIR Res Protoc* 2021; 10(1): e24414.

13. Van der Willik KD, Yilmaz P, Compter A, **Hauptmann M**, Jozwiak K, Ruiter R, Stricker BH, Vernooij MW, Ikram MA, De Ruiter MB, Schagen SB. Brain structure prior to non-central nervous system cancer diagnosis: a population-based cohort study. *Neuroimage Clin* 2020; 28:102466.
14. Nachtigall I, Lenga P, Jozwiak K, Thürmann P, Meier-Hellmann A, Kuhlen R, Brederlau J, Bauer T, Tebbenjohanns J, Schwegmann K, **Hauptmann M**, Dengler J. Clinical course and outcomes of patients with COVID-19 in Germany: a multicenter, retrospective, observational study. *Clin Microbiol Infect* 2020; 26(12): 1663–1669.
15. Kramer I, Hooning MJ, Mavaddat N, **Hauptmann M**, Keeman R, Steyerberg EW, Giardiello D, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Antoniou AC, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castela JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL, NBCS Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dork T, dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, Garcia-Closas M, Garcia-Saenz JA, Giles GG, Goldgar DE, Gonzalez-Neira A, Haiman CA, Hakansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A, ABCTB Investigators, kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubinski J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan A M, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkas K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengstrom M, Teo SH, Terry MB, Tollenaar RA, Tomlinson I, Troester MA, Vachon CM, Van Ongeval C, Van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK. Breast cancer polygenic risk score and contralateral breast cancer risk. *Am J Hum Genet* 2020; 107(5): 837–848.
16. De Boer M, **Hauptmann M**, Hijmering NJ, Van Noesel CJ, Rakhorst HA, Meijers-Heijboer HE, De Boer JP, Van der Hulst RR, De Jong D, Van Leeuwen FE. Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast. *Blood* 2020; 136(11): 1368–1372.
17. Giardiello D, Kramer I, Hooning MJ, **Hauptmann M**, Lips EH, Sawyer E, Thompson AM, de Munck L, Siesling S, Wesseling J, Steyerberg EW, Schmidt MK. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. *NPJ Breast Cancer* 2020; 6(1): 60.
18. Klinkhammer-Schalke M, Kaiser T, Apfelbacher C, Benz C, Dreinhöfer K, Geraedts M, **Hauptmann M**, Hoffmann F, Hoffmann W, Holland J, Koller M, Kostuj T, Kowalski C, Mugele K, Ortman O, Schmitt J, Schünemann H, Veit C, Wesselmann S, Bierbaum T. Manual für Methoden und Nutzung versorgungsnaher Daten zur Wissensgenerierung. *Gesundheitsforschung* 2020; 82: 716–722.
19. Berrington de Gonzalez A, Daniels RD, Cardis E, Cullings H, Gilbert ES, **Hauptmann M**, Kendall GM, Laurier D, Linet MS, Little MP, Lubin JH, Preston DL, Richardson DB, Stram DO, Thierry-Chef I, Schubauer-Berigan M. Epidemiological studies of the low-dose ionizing radiation and cancer: rationale for the monograph and overview of the eligible studies. *JNCI Monogr* 2020; 56: 97–113.
20. Schubauer-Berigan MK, Berrington de Gonzalez A, Cardis E, Laurier D, Lubin JH, **Hauptmann M** (joint senior author), Richardson DB. Evaluation of confounding and selection bias in epidemiologic studies of populations exposed to low-dose, high-energy photon radiation. *JNCI Monogr* 2020; 56: 133–153.
21. **Hauptmann M**, Daniels RD, Cardis E, Cullings H, Kendall GM, Laurier D, Linet MS, Little MP, Lubin JH, Preston DL, Richardson DB, Stram DO, Thierry-Chef I, Schubauer-Berigan M, Gilbert ES,

- Berrington de Gonzalez A. Epidemiological studies of low-dose ionizing radiation and cancer: summary bias assessment and meta-analysis. *JNCI Monogr* 2020; 56: 188–200.
22. Journy N, Schonfeld S, **Hauptmann M**, Roberti S, Howell RM, Smith SA, Vaalavirta L, Stovall M, Van Leeuwen FE, Weathers RE, Hodgson D, Hall P, Aleman B, Gilbert ES, Berrington de Gonzalez A, Morton LM. Dose-volume effects of breast cancer radiotherapy on the risk of second esophageal tumor. *Radiother Oncol* 2020; 151: 33–39.
 23. Rehani M, **Hauptmann M**. Estimates of number of patients with high cumulative doses through recurrent CT exams in 35 OECD countries. *Phys Med* 2020; 76: 173–176.
 24. Wollersheim BM, Van Asselt KM, Van der Poel HG, Van Weert HC, **Hauptmann M**, Retel VP, Aaronson NK, Van de Poll-Franse LV, Boekhout AH. Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): A randomized controlled trial to evaluate the effectiveness of primary care based follow-up care of prostate cancer survivors. *BMC Cancer* 2020; 20(1): 635.
 25. Van der Willik KD, **Hauptmann M**, Jozwiak K, Vinke EJ, Ruiter R, Stricker BH, Compter A, Ikram A, Schagen SB. Trajectories of cognitive function prior to cancer diagnosis: a population-based study. *J Natl Cancer Inst* 2020; 112(5): 480–488.
 26. Giardiello D, **Hauptmann M**, Steyerberg EW, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, Garcia-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HS, Pelders S, Pharoah PD, Shah M, Siesling S, Smit VT, Southey MC, Tapper WJ, Tollenaar RA, Van den Broek AJ, Van Deurzen CH, Van Leeuwen FE, Van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. *Breast Cancer Res Treat* 2020; 181(2): 423–434.
 27. Zavrakidis I, Jozwiak K, **Hauptmann M**. Statistical analysis of longitudinal data on tumour growth in mice experiments. *Sci Rep* 2020; 10(1): 9143.
 28. Boekel NB, Duane FK, Jacobse JN, **Hauptmann M**, Schaapveld M, Sonke GS, Gietema JA, Hooning MJ, Seynaeve CM, Maas AH, Darby SC, Aleman BM, Taylor CW, Van Leeuwen FE. Heart failure after treatment for breast cancer. *Eur J Heart Fail* 2020; 22(2): 366–374.
 29. De Boer M, Van Middelkoop M, **Hauptmann M**, Van der Bijl N, Bosmans J, Hendriks-Brouwer N, Schop S, De Boer JP, Overbeek LI, Lobbes MB, Klazen CA, De Jong D, Rakhorst HA, Van der Hulst RR, Van Leeuwen FE. Breast implant prevalence in the Dutch female population assessed by chest radiographs. *Aesthet Surg J* 2020; 40(2): 156–164.
 30. Hessen E, Nijkamp J, Damen P, **Hauptmann M**, Jasperse B, Dewit L, Lutkenhaus L, Lamers E, Van der Heide U, Damen E, Hanssens P, Borst G. Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. *Radiother Oncol* 2020; 142: 175–179.
 31. Teepen JC, Kok JL, Kremer LC, Tissing WJ, Van den Heuvel-Eibrink MM, Loonen JJ, Bresters D, Van der Pal HJ, Versluys B, Van Dulmen-den Broeder E, Nijsten T, **Hauptmann M**, Hollema N, Dolsma WV, Van Leeuwen FE, Ronckers CM, DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. *J Natl Cancer Inst* 2019; 111(8): 845–853.
 32. Kok JL, Teepen JC, Van Leeuwen FE, Tissing WJ, Neggers SJ, Van der Pal HJ, Loonen HJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-den Broeder E, Van der Heiden-van der Loo M, Aleman B, Daniels L, Haasbeek C, Hoeben B, Janssens G, Maduro J, Oldenburger F, Van Rij C, Tersteeg R, **Hauptmann M**, DCOG-LATER Study Group, Kremer LC, Ronckers CM. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. *Neuro Oncol* 2019; 21(3): 392–403.

33. Bernier MO, Baysson H, Pearce MS, Moissonnier M, Cardis E, **Hauptmann M**, Struelens L, Dabin J, Johansen C, Journy N, Laurier D, Blettner M, Le Cornet L, Pokora R, Gradowska P, Meulepas JM, Kjaerheim K, Istad T, Olerud H, Sovik A, Bosch de Basea M, Thierry-Chef I, Kaijser M, Nordenskjold A, Berrington de Gonzalez A, Harbron RW, Kesminiene A. The EPI-CT study: a European pooled epidemiological study to quantify the potential radiation-induced risks associated to paediatric CT-scans. *Int J Epidemiol* 2019; 48(2): 379–381.
34. Puppe J, Opdam M, Schouten PC, Jozwiak K, Lips E, Severson T, Van de Ven M, Brambillasca C, Bouwman P, Van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretic L, Caldas C, Van Lohuizen M, **Hauptmann M**, Rhiem K, Hahnen E, Reinhardt HC, Buettner R, Mallmann P, Schoemig-Markiefka B, Schmutzler B, Linn S, Jonkers J. EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy. *Clin Cancer Res* 2019; 25(14): 4351–4362.
35. Giardiello D, Steyerberg EW, **Hauptmann M**, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PM, Figueroa J, Flyger H, Garcia-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Manoochchri M, Mariani L, Nevanlinna H, Oldenburg HS, Pelders S, Pharoah PD, Shah M, Siesling S, Smit VT, Southey MC, Tapper WJ, Tollenaar RA, Van den Broek AJ, Van Deurzen CH, Van Leeuwen FE, Van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt M. Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Res* 2019; 21(1): 144.
36. Spaan M, Van den Belt-Dusebout AW, Van den Heuvel-Eibrink MM, **Hauptmann M**, Lambalk CB, Burger CW, Van Leeuwen FE, on behalf of the OMEGA-steering group. Risk of cancer in children and young adults conceived by assisted reproductive technology. *Hum Reprod* 2019; 34(4): 740–750.
37. Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Gradowska P, Lee C, Jahnen A, Van Straten M, De Wit MC, Zonnenberg B, Klein WM, Merks JH, Visser O, Van Leeuwen FE, **Hauptmann M**. Radiation exposure from pediatric CT scans and subsequent cancer risk in the Netherlands. *J Natl Cancer Inst* 2019; 111(3): 256–263.
38. Opstal-Van Winden AW, De Haan HG, **Hauptmann M**, Schmidt MK, Broeks A, Russell NS, Janus CP, Krol AD, Van der Baan FH, De Bruin ML, Van Eggermond AM, Dennis J, Culver HA, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr P, Easton DF, Aleman BM, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, Van Leeuwen FE. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. *Blood* 2019; 133(10): 1130–1139.
39. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hooning MJ, Seynaeve CM, Baaijens MH, **Hauptmann M**, Gietema JA, Aleman BM, Taylor BM, Darby BM, Van Leeuwen FE. Radiation dose-response for risk of myocardial infarction in breast cancer survivors. *Int J Radiat Oncol Biol Phys* 2019; 103(3): 595–604.
40. Van den Berg MH, Overbeek A, Lambalk CB, Kaspers GJ, Bresters MM, Van den Heuvel-Eibrink MM, Kremer LC, Loonen JJ, Van der Pal HJ, Ronckers CM, Tissing WJ, Versluys AB, Van der Heiden-Van der Loo AC, Heijboer AC, **Hauptmann M**, Twisk JW, Laven JS, Beerendonk CC, Van Leeuwen FE, Van Dulmen-Den Broeder E, on behalf of the DCOG LATER-VEVO study group. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian function. *Hum Reprod* 2018; 33(8): 1474–1488.
41. Van Gils T, Nijeboer P, Overbeek LI, **Hauptmann M**, Castelijin DA, Bouma G, Mulder CJ, Van Leeuwen FE, De Jong D. Risks for lymphoma and gastrointestinal carcinoma in patients with newly diagnosed adult-onset celiac disease: consequences for follow-up. *United European Gastroenterol J* 2018; 6(10): 1485–1495.

42. Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, Van den Broek AJ, **Hauptmann M**, Steyerberg EW, Hooning MJ. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. *Breast* 2018; 44: 1–14.
43. Van der Willik KD, Koppelmans V, **Hauptmann M**, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. *Breast Cancer Res* 2018; 20(1): 135.
44. Lubin JH, **Hauptmann M**, Blair A. Indirect adjustment of an exposure with multiple categories for an unmeasured confounder. *Ann Epidemiol* 2018; 28(11): 801–807.
45. Halldorsson MO, **Hauptmann M**, Snabjornsson P, Haraldsdottir KH, Eiriksdottir G, Aspelund T, Guamundsson EF, Guanason V, Jonasson JG, Haraldsdottir S. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy. *Scand J Gastroenterol* 2018; 53(8): 972–975.
46. Wojcik A, Bouffler S, **Hauptmann M**, Rajaraman P. Considerations on the use of the terms radiosensitivity and radiosusceptibility. *J Radiol Prot* 2018; 38(3): N25–N29.
47. Krul IM, Opstal-Van Winden AW, Zijlstra AW, Appelman Y, Schagen SB, Meijboom L, Serne E, Lambalk CB, Lips CB, Van Dulmen-den Broeder E, **Hauptmann M**, Daniels LA, Aleman BM, Van Leeuwen FE. Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin lymphoma: influence on long-term adverse effects (SOPHIA). *BMJ Open* 2018; 8(9): e018120.
48. Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, **Hauptmann M**, Seynaeve CM, Baaijens MH, Sonke GS, Rutgers EJ, Russell NS, Aleman BM, Van Leeuwen FE. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. *Br J Cancer* 2018; 119: 408–418.
49. Rajaraman P, **Hauptmann M**, Bouffler S, Wojcik A. Human individual radiation sensitivity and prospects for prediction. *Ann ICRP* 2018; 47(3-4): 126–141.
50. Teepen JC, Kok JL, Van Leeuwen FE, Tissing WJ, Dolsma WV, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Van den Heuvel-Eibrink MM, Van Dulmen-Den Broeder E, Van den Berg MH, **Hauptmann M**, Jongmans MC, Overbeek LI, Van de Vijver MJ, Kremer LC, Ronckers CM, on behalf of the DCOG-LATER Study Group. Colorectal adenomas and cancers after childhood cancer treatment: a DCOG-LATER record linkage study. *J Natl Cancer Inst* 2018; 110(7): 758–767.
51. Van der Willik K, Ruiters R, Wolters FJ, Ikram MK, Stricker BH, **Hauptmann M**, Compter A, Schagen SB, Ikram MA. Mild cognitive impairment and dementia show contrasting associations with risk of cancer. *Neuroepidemiology* 2018; 50(3–4): 207–215.
52. De Boer M, Van Leeuwen FE, **Hauptmann M**, Overbeek LI, De Boer JP, Hijmering NJ, Sernee A, Klazen CA, Lobbes MB, Van der Hulst RR, Rakhorst HA, De Jong D. Breast implants and the risk of anaplastic large cell lymphoma in the breast. *JAMA Oncol* 2018; 4(3): 335–341.
53. Meulepas JM, **Hauptmann M**, Lubin JH, Shuryak I, Brenner DJ. Is there unmeasured indication bias in radiation-related cancer risk estimates from studies of computed tomography? *Radiat Res* 2018; 189(2): 128–135.
54. Van Griethuysen JJ, Bus EM, **Hauptmann M**, Lahaye MJ, Maas M, Ter Beek L, Beets GL, Bakers FC, Beets-Tan RG, Lambregts DM. Gas-induced susceptibility artifacts on diffusion-weighted MRI of the rectum – effect of applying a micro-enema to improve image quality. *Eur J Radiol* 2018; 99: 131–137.
55. Dackus GM, Jozwiak K, Sonke GS, Van der Wall E, Van Diest PJ, **Hauptmann M**, Siesling S, Linn SC. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: a population-based cohort study. *Eur J Cancer* 2018; 90: 92–101.

56. Russell NS, Van Eggermond A, Aleman A, Krul I, Cooke R, Kuiper S, Allen SD, Wallis MG, Diallo I, De Vathaire F, **Hauptmann M**, Swerdlow AJ, Van Leeuwen FE. Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. *Clin Transl Rad Oncol* 2017; 7: 20–27.
57. Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop EA, Willems SM, Van Deurzen CH, Groen EJ, Cordoba-Iturriagagoitia A, Bart J, Mooyaart AL, Van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Jozwiak K, **Hauptmann M**, Hoogstraat M, Wessels LF, Schmidt MK, Sonke GS, Van der Wall E, Siesling S, Van Diest PJ, Linn SC. Long-term prognosis of young breast cancer patients (≤ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. *BMJ Open* 2017; 7(11): e017842.
58. Krul IM, Opstal–Van Winden AW, Aleman BM, Janus CP, Van Eggermond AM, De Bruin ML, **Hauptmann M**, Krol AD, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, Van der Maazen RW, Kesminiene A, Diallo I, De Vathaire F, Russell NS, Van Leeuwen FE. Breast cancer risk after radiotherapy for Hodgkin lymphoma: influence of gonadal hormone exposure. *Int J Radiat Oncol Biol Phys* 2017; 99(4): 843–853.
59. Teepen JC, Van Leeuwen FE, Tissing WJ, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink MM, Van der Pal HJ, Loonen JJ, Bresters D, Versluys B, Neggers SJ, **Hauptmann M**, Van der Heiden-van der Loo M, Visser O, Kremer LC, Ronckers CM on behalf of the DCOG LATER Study Group. Long-term risk of subsequent malignant neoplasms after treatment for childhood cancer in the DCEG LATER cohort study: role of chemotherapy. *J Clin Oncol* 2017; 35(20): 2288–2298.
60. Van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, **Hauptmann M**, Lugtenburg PJ, Janus C, Daniels L, Van Leeuwen FE, Cutter DJ, Aleman BM. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. *Blood* 2017; 129(16): 2257–2265.
61. Meulepas JM, Ronckers CM, Gradowska P, Nievelstein RA, Van der Lee F, Mourik J, De Lange F, Smets AM, **Hauptmann M**. Trends and patterns of computed tomography scans among children in the Netherlands: 1990–2012. *European Radiology* 2017; 27(6): 2426–2433.
62. Gilbert E, Curtis RE, **Hauptmann M**, Kleinerman RA, Lynch CF, Stovall M, Smith SA, Weathers R, Andersson M, Dores GM, Fraumeni Jr JF, Fossa SD, Hall P, Hodgson DC, Holowaty EJ, Joensuu H, Johannesen TB, Langmark F, Kaijser M, Pukkala E, Rajaraman E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Aleman BM, Travis LB, Morton LM, Van Leeuwen FE. Stomach cancer following Hodgkin lymphoma, testicular cancer, and cervical cancer: A pooled analysis of three international studies with a focus on radiation effects. *Radiat Res* 2017; 187(2): 186–195.
63. Meulepas JM, Ronckers CM, Merks JH, Weijerman ME, Lubin JH, **Hauptmann M**. Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes. *J Radiol Prot* 2016; 36(4): 953–974.
64. De Ridder M, Marres CC, Smeele LE, Van den Brekel MW, **Hauptmann M**, Balm AJ, Van Velthuysen ML. A critical evaluation of lymph node ratio in head and neck cancer. *Virchows Arch* 2016; 469(6): 635–641.
65. **Hauptmann M**, Johannesen TB, Gilbert ES, Stovall M, Van Leeuwen FE, Rajaraman P, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Morton LM, Fossa SD, Travis LB. Increased pancreatic cancer risk following radiotherapy for testicular cancer. *Br J Cancer* 2016; 115: 901–908.

66. Van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JS, Van Santbrink EJ, Van der Westerlaken LA, Cohlen BJ, Braat DD, Smeenk JM, Land JA, Goddijn M, Van Golde RJ, Van Rumste MM, Schats R, Jozwiak K, **Hauptmann M**, Rookus MA, Burger CW, Van Leeuwen FE. Association between ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. *JAMA* 2016; 316(3): 300–312.
67. Droog M, Nevedomskaya E, Kim Y, Severson T, Flach K, Opdam M, Schuurman K, Gradowska P, **Hauptmann M**, Dackus G, Hollema H, Mourits M, Nederlof P, Van Boven H, Linn S, Wessels LF, Van Leeuwen FE, Zwart W. Comparative cistromics reveals genomic crosstalk between FOXA1 and ER α in tamoxifen-associated endometrial carcinomas. *Cancer Res* 2016; 76(13): 3773–3784.
68. Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, **Hauptmann M**, Linn SC. High expression of XIST and low expression of 53BP1 predict poor outcome after high dose alkylating chemotherapy in BRCA1-like breast cancer. *Mol Cancer Therapeutics* 2016; 15(1): 190–198.
69. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, **Hauptmann M**, Kooijman K, Roesink J, Van der Maazen R, Darby SC, Aleman BM, Van Leeuwen FE. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. *J Clin Oncol* 2016; 34(3): 235–243.
70. Kuijpers A, **Hauptmann M**, Aalbers A, Nienhuijs S, De Hingh I, Wiezer R, Van Ramshorst B, Van Ginkel R, Havenga K, Verwaal V. Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve re-assessed. *Eur J Surg Oncol* 2016; 42(2): 244–250.
71. Theunissen EA, Zuur CL, Jozwiak K, Lopez-Yurda M, **Hauptmann M**, Rasch CR, Van der Baan S, De Boer JP, Dreschler WA, Balm AJ. Prediction of hearing loss due to cisplatin chemoradiotherapy. *JAMA Otolaryngol Head Neck Surg* 2015; 141(9): 810–815.
72. Bentin Toaldo C, Alexi X, Beelen K, Kok M, **Hauptmann M**, Jansen M, Berns E, Neeffjes J, Linn S, Michalides R, Zwart W. Protein kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. *BMC Cancer* 2015; 15: 588.
73. Bosch de Basea M, Pearce MS, Kesminiene A, Bernier MO, Dabin J, Engels H, **Hauptmann M**, Krille L, Meulepas JM, Struelens L, Baatout S, Kaijser M, Maccia C, Jahnen A, Thierry-Chef I, Blettner M, Johansen C, Kjaerheim K, Nordenskjöld A, Olerud H, Salotti JA, Andersen TV, Vrijheid M, Cardis E. EPI-CT: Design, challenges and epidemiological methods of an international study on cancer risk after paediatric CT. *J Radiol Prot* 2015; 35(3): 611–628.
74. Pearce N, Blair A, Vineis P, Anto J, Armstrong B, Attfield M, Baccarelli A, Beane Freeman L, Beland F, Berrington A, Bertazzi P, Birnbaum L, Bucher J, Cardis E, Cherrie J, Christiani D, Cocco P, Coggon D, Comba P, Demers P, Dement J, Douwes J, Engel L, Fletcher T, Fontham E, Forastiere F, Friesen M, Fritschi L, Gerin M, Goldberg M, Grandjean P, Gustavsson P, Hartge P, Hansen J, **Hauptmann M**, Heederick D, Hoppin J, Huff J, Jarvholm B, Karagas M, Kjuus H, Kogevinas M, Kriebel D, Kristensen P, Kromhout H, Laden F, Lebailly P, Lemasters G, Lubin J, Lynch C, Lynge E, Mannelteje A, McLaughlin J, Merchant J, Merletti F, Miller A, Parent ME, Perry M, Pesatori A, Pirastu R, Porta M, Pukkala E, Rice C, Ritz B, Ruder A, Rushton L, Rusyn I, Samet J, De Sanjose S, Saracci R, Schernhammer E, Schulte P, Sexias N, Silvermann D, Simonato L, Smith A, Spinelli J, Stayner L, Steenland K, Stenzel T, Stewart B, Stewart T, Symanski E, Terracini B, Vainio H, Vena J, Vermeulen R, Victora C, Wagner G, Ward E, Weinberg C, Weisenburger D, Whelan B, Zahm S, Zhang Y. Evidence assessment for Public Health: the 40 years work of the IARC Monographs. *Environ Health Persp* 2015; 123(6): 507–514.
75. Schouten PC, Marme F, Aulmann S, Sinn HP, Van Essen HJ, Ylstra B, **Hauptmann M**, Schneeweiss A, Linn SC. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. *Clin Cancer Res* 2015; 21(4): 763–770.

76. Cutter D, Schaapveld M, Darby SC, **Hauptmann M**, Van Nimwegen FA, Krol SA, Janus C, Van Leeuwen FE, Aleman BM. Risk of valvular heart disease after radiotherapy for Hodgkin lymphoma. *J Natl Cancer Inst* 2015; 107(4).
77. Groenendijk FH, Mellema WW, Van der Burg E, Schut E, **Hauptmann M**, Horlings HM, Willems SM, Van den Heuvel MM, Jonkers J, Smit EF, Bernards R. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. *Int J Cancer* 2015; 136(6): 1434–1444.
78. Kuijpers AM, Aalbers AG, Nienhuijs SW, De Hingh IH, Wiezer MJ, Van Ramshorst B, Van Ginkel RJ, Havenga K, Heemsbergen WD, **Hauptmann M**, Verwaal VJ. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. *World J Surg* 2015; 39(2): 453–460.
79. **Hauptmann M**, Fossa SD, Stovall M, Van Leeuwen FE, Johannesen TB, Rajaraman P, Gilbert ES, Smith SA, Weathers RE, Aleman BM, Andersson M, Curtis RE, Dores GM, Fraumeni Jr JF, Hall P, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Lynch CF, Pukkala E, Storm HH, Vaalavirta L, Van den Belt-Dusebout AW, Travis LB, Morton LM. Increased stomach cancer risk following radiotherapy for testicular cancer. *Br J Cancer* 2015; 112(1): 44–51.
80. Krul IM, Groeneveld E, Spaan M, Van den Belt-Dusebout AW, Mooij TM, **Hauptmann M**, Twisk JW, Lambers MJ, Hompes PG, Burger CW, Lambalk CB, Van Leeuwen FE on behalf of the OMEGA-project group. Increased breast cancer risk in IVF treated women with a multiple pregnancy: a new hypothesis based on old IVF treatment data. *Eur J Cancer* 2015; 51(1): 112–120.
81. Theunissen EA, Zuur CL, Bosma SC, Lopez Yurda M, **Hauptmann M**, Van der Baan S, De Boer JP, Van der Molen L, Rasch CR, Dreschler WA, Balm AJ. Long-term hearing loss after chemoradiation in patients with head and neck cancer. *Laryngoscope* 2014; 124(12): 2720–2725.
82. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Van de Vijver MJ, De Vries EG, Van Tinteren H, Jonkers J, **Hauptmann M**, Rodenhuis S, Linn SC. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. *Breast Cancer Res* 2014; 16(3): R47.
83. Meulepas JM, Ronckers CM, Smets AM, Nievelstein RA, Jahnen A, Lee C, Kieft M, Lameris JS, Van Herk M, Greuter MJ, Jeukens CR, Van Straten M, Visser O, Van Leeuwen FE, **Hauptmann M**. Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. *Eur J Epidemiol* 2014; 29(4): 293–301.
84. Kuijpers AM, Mehta AM, Boot H, Van Leerdam ME, **Hauptmann M**, Aalbers AG, Verwaal VJ. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Oncol* 2014; 25(4): 864–869.
85. Marres CC, De Ridder MD, Hegger I, Van Velthuysen ML, **Hauptmann M**, Navran A, Balm AJ. The influence of nodal yield in neck dissections on lymph node ratio in head and neck cancer. *Oral Oncol* 2014; 50(1): 59–64.
86. Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Aleman BM, Hodgson DC, Storm HH, Johannesen TB, Smith SA, Weathers RE, Andersson M, Fossa SD, **Hauptmann M**, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta L, Van den Belt-Dusebout AW, Fraumeni Jr. JF, Travis LB, Van Leeuwen FE. Stomach cancer risk after treatment for Hodgkin lymphoma. *J Clin Oncol* 2013; 31(27): 3369–3377.
87. Stiekema J, Cats A, Kuijpers A, Van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, **Hauptmann M**, Van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? *Eur J Surg Oncol* 2013; 39(7): 686–693.

88. Beelen K, Opdam M, Severson T, Koornstra RH, Vincent AD, **Hauptmann M**, Van Schaik RH, Berns EM, Vermorken JB, Van Diest PJ, Linn SC. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. *Breast Cancer Res Treat* 2013; 139(3): 649–655.
89. Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, **Hauptmann M**. Mortality from solid tumors among workers in formaldehyde industries: an update of the NCI cohort. *Am J Ind Med* 2013; 56: 1015–1026.
90. Schouten PC, Van Dyk E, Braaf LM, Mulder L, Lips EH, De Ronde JJ, Holtman L, Wesseling J, **Hauptmann M**, Wessels LF, Linn SC, Nederlof PM. Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. *Breast Cancer Res Treat* 2013; 139(2): 317–327.
91. Lodder WL, Lange CA, Van Velthuysen ML, **Hauptmann M**, Balm AJ, Van den Brekel MW, Pameijer FA. Can extranodal spread in head and neck cancer be detected on MR imaging. *Oral Oncol* 2013; 49(6): 626–633.
92. Van Monsjou HS, Lopez-Yurda M, **Hauptmann M**, Van den Brekel MW, Balm AJ, Wreesmann VB. Oral and oropharyngeal squamous cell carcinoma in young patients: The Netherlands Cancer Institute experience. *Head Neck* 2013; 35(1): 94–102.
93. Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, GENEPSO, Nogues C, Gauthier-Villars M, Lasset C, Fricker JP, EMBRACE, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, HEBON, Manders P, Van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, **Hauptmann M**, Goldgar D, Rookus MA, Van Leeuwen FE. Diagnostic radiation exposure and breast cancer risk in BRCA1/2 mutation carriers in the GENE-RAD-RISK study. *BMJ* 2012; 345: e5660.
94. Kok M, Koornstra RH, Mook S, **Hauptmann M**, Fles R, Simon I, Glas A, Jansen MP, Berns EM, Foekens JA, Linn SC, Van 't Veer LJ. Additional value of 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. *Breast* 2012; 21: 769–778.
95. Kreeft AM, Smeele LE, Rasch CR, **Hauptmann M**, Rietveld DH, Leemans CR, Balm AJ. Preoperative imaging and surgical margins in maxillectomy patients. *Head Neck* 2012; 34(11): 1652–1656.
96. Ackerstaff AH, Rasch CR, Balm AJ, De Boer JP, Wiggenraad R, Rietveld DH, Gregor RT, Kroger R, **Hauptmann M**, Vincent A, Hilgers FJ. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. *Head Neck* 2012; 34(7): 974–980.
97. Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, Van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, De Vries EG, Schrama JG, Wesseling J, Van de Vijver MJ, Van Tinteren H, De Bruin M, **Hauptmann M**, Rodenhuis S, Linn SC. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. *Ann Oncol* 2011; 22(7): 1561–1570.
98. Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, **Hauptmann M**, Voest EE, Schellens JH, Van't Veer LJ. A multi-marker QPCR-based platform for the detection of circulating tumor cells in patients with early-stage breast cancer. *Br J Cancer* 2011; 104(12): 1913–1919.
99. Knegjens JL, Pameijer FA, **Hauptmann M**, Balm AJ, Hoebbers FJ, De Bois JA, Kaanders JH, Verhoef LC, Wijers OB, Wiggenraad RG, Buter J, Rasch CR. Tumor volume as outcome predictor in chemoradiation for advanced head and neck cancer. *Head Neck* 2011; 33(3): 375–382.
100. Kok M, Zwart W, Holm C, Fles R, **Hauptmann M**, Van 't Veer LJ, Wessels LF, Neefjes J, Stal O, Linn SC, Landberg G, Michalides R. PKA-induced phosphorylation of ER α at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. *Breast Cancer Res Treat* 2011; 125: 1–12.

101. Vollebergh MA, Kappers I, Klomp HM, Buning-Kager JC, Korse CM, Bonfrer JM, **Hauptmann M**, De Visser KE, Van den Heuvel MM, Linn SC. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. *J Thorac Oncol* 2010; 5(12): 1939–1948.
102. Borst GR, Ishikawa M, Nijkamp J, **Hauptmann M**, Shirato H, Bengua G, Onimaru R, De Bois JA, Lebesque JV, Sonke JJ. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. *Int J Radiat Oncol Biol Phys* 2010; 77(5): 1596–1603.
103. Van der Pal HJ, Van Dalen EC, **Hauptmann M**, Kok WE, Caron HN, Van den Bos C, Oldenburger F, Koning CC, Van Leeuwen FE, Kremer LC. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. *Arch Intern Med* 2010; 170(14): 1247–1255.
104. Knauer M, Mook S, Rutgers EJ, Bender RA, **Hauptmann M**, Van de Vijver M, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, Van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. *Breast Cancer Res Treat* 2010; 120(3): 655–661.
105. De Jong MC, Pramana J, Kneijens JL, Balm AJ, Van den Brekel MW, **Hauptmann M**, Begg AC, Rasch CR. HPV and high risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer independent of clinical factors. *Radiother Oncol* 2010; 95(3): 365–370.
106. Rasch CR, **Hauptmann M**, Schornagel J, Wijers O, Buter J, Gregor T, Wiggenraad R, De Boer JP, Ackerstaff AH, Kroger R, Hoebbers FJ, Balm AJ. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase III trial. *Cancer* 2010; 116(9): 2159–2165.
107. Retel VP, Joore MA, Knauer M, Linn SC, **Hauptmann M**, Van Harten WH. Cost-effectiveness of the 70-gene signature versus Sankt Gallen guidelines and Adjuvant Online for early breast cancer. *Eur J Cancer* 2010; 46(8): 1382–1391.
108. Brown LM, Gridley G, Wu AH, Falk RT, **Hauptmann M**, Kolonel LN, West DW, Nomura AMY, Pike MC, Hoover RN, Ziegler RG. Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women. *Breast Cancer Res Treat* 2010; 120: 203–210.
109. Zhang L, Tang X, Rothman N, Vermeulen R, Ji Z, Shen M, Qiu C, Guo W, Liu S, Reiss B, Beane Freeman L, Ge Y, Hubbard AE, Hua M, Blair A, Galvan N, Ruan X, Alter BP, Xin KX, Li S, Moore LE, Kim S, Xie Y, Hayes RB, Azuma M, **Hauptmann M**, Xiong J, Stewart PA, Li L, Rappaport SM, Huang H, Fraumeni Jr. JF, Smith MT, Lan Q. Occupational exposure to formaldehyde, hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 80–88.
110. Kok M, Holm-Wigerup C, **Hauptmann M**, Michalides R, Stal O, Linn S, Landberg G. Estrogen receptor- α phosphorylation at serine-118 and tamoxifen response in breast cancer. *J Natl Cancer Inst* 2009; 101: 1725–1729.
111. **Hauptmann M**, Stewart PA, Lubin JH, Beane Freeman LE, Hornung RW, Herrick RF, Hoover RN, Fraumeni JF Jr, Blair A, Hayes RB. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde in the funeral industry. *J Natl Cancer Inst* 2009; 101: 1696–1708.
112. Van den Belt-Dusebout AW, Aleman BM, Besseling G, De Bruin ML, **Hauptmann M**, Van 't Veer MB, De Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. *Int J Radiat Oncol Biol Phys* 2009; 75: 1420–1429.
113. Borst GR, Ishikawa M, Nijkamp J, **Hauptmann M**, Shirato H, Onimaru R, Van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. *Radiother Oncol* 2009; 91: 307–313.

114. Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, **Hauptmann M**. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: update of the NCI cohort. *J Natl Cancer Inst* 2009; 101: 751–761.
115. Wildeman MA, Gibcus JH, **Hauptmann M**, Begg AC, Van Velthuysen ML, Hoebbers FJ, Mastik MF, Schuurung E, Van der Wal JE, Van den Brekel MW. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? *Laryngoscope* 2009; 119: 316–322.
116. Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, **Hauptmann M**, Neefjes J, Peterse JL, Stal O, Landberg G, Linn SC. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. *J Pathol* 2009; 217: 372–379.
117. Pietersen AM, Horlings HM, **Hauptmann M**, Langerod A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, Van de Vijver MJ, Van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. *Breast Cancer Res* 2009; 10: R109.
118. Kok M, Linn SC, Van Laar RK, Jansen MP, Van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, **Hauptmann M**, Foekens JA, Klijn JG, Wessels LF, Van 't Veer LJ, Berns EM. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. *Breast Cancer Res Treat* 2009; 113: 275–283.
119. Hooning MJ, Aleman BM, **Hauptmann M**, Baaijens MH, Klijn JG, Noyon R, Stovall M, Van Leeuwen FE. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. *J Clin Oncol* 2008; 26: 5561–5568.
120. Berhane K, **Hauptmann M**, Langholz B. Using tensor product splines in modeling exposure-time-response relationships: application to the Colorado Plateau uranium miners cohort. *Stat Med* 2008; 27: 5484–5496.
121. Weigelt B, Horlings HM, Kreike B, Hayes MM, **Hauptmann M**, Wessels LF, De Jong D, Van de Vijver MJ, Van 't Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. *J Pathol* 2008; 216: 141–150.
122. Chodick G, Bekiroglu N, **Hauptmann M**, Alexander BH, Freedman DM, Doody MM, Cheung LC, Simon SL, Weinstock RM, Bouville A, Sigurdson AJ. Risk of cataract after exposure to low doses of ionizing radiation: a 20-year prospective cohort study among US radiologic technologists. *Am J Epidemiol* 2008; 168: 620–631.
123. Sigurdson AJ, Ha M, **Hauptmann M**, Bhatti P, Sram R, Beskid O, Tawn EJ, Whitehouse CA, Lindholm C, Nakano M, Kodama Y, Nakamura N, Vorobstova I, Oestreicher U, Stephan G, Yong LC, Bauchinger M, Schmid E, Chung HW, Darroudi F, Roy L, Voisin P, Barquinero JF, Livingston G, Blakey D, Hayata I, Zhang W, Wang C, Bennett LM, Littlefield LG, Edwards AA, Kleinerman RA, Tucker JD. International study of factors affecting human chromosome translocations. *Mutat Res* 2008; 652: 112–121.
124. Ji BT, Blair A, Shu XO, Dosemeci M, **Hauptmann M**, Yang G, Chow WH, Lubin JH, Gao YT, Rothman N, Zheng W. Occupation and breast cancer risk among Shanghai women in a population-based cohort study. *Am J Ind Med* 2008; 51: 100–110.
125. De Bruin ML, Huisbrink J, **Hauptmann M**, Kuenen MA, Ouwens GM, Van 't Veer MB, Aleman BM, Van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. *Blood* 2008; 111: 101–108.
126. Bhatti P, Struewing JP, Alexander BH, **Hauptmann M**, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. radiologic technologists. *Int J Cancer* 2008; 122: 177–182.

127. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Ajouaou A, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, **Hauptmann M**, Beijersbergen RL, Mills GB, Van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer. *Cancer Cell* 2007; 12: 395–402.
128. Sigurdson AJ, Bhatti P, Doody MM, **Hauptmann M**, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struewing JP, Rajaraman P. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 2000–2007.
129. Lubin JH, Caporaso N, Alavanja M, Wichmann HE, Schaffrath-Rosario A, Krewski D, Zielinski JM, Brownson R, Field RW, Letourneau EG, Lynch CF, Sandler DP, Schoenberg JB, Wilcox HB, Kleinerman R, Wang Z, **Hauptmann M**, Langholz B, Hartge P, Garcia-Closas M, Hayes RB, Silverman DT, Brown LM. Cigarette smoking and cancer: modeling total exposure and intensity. *Am J Epidemiol* 2007; 166: 479–89.
130. Ha M, Mabuchi K, Sigurdson AJ, Freedman MD, Linet MS, Doody MM, **Hauptmann M**. Smoking cigarettes before first childbirth increases risk of breast cancer. *Am J Epidemiol* 2007; 166: 55–61.
131. Bhatti P, Preston DL, Doody MM, **Hauptmann M**, Kampa D, Alexander BH, Petibone D, Simon SL, Weinstock RM, Bouville A, Yong LC, Freedman DM, Mabuchi K, Linet MS, Edwards AA, Tucker JD, Sigurdson AJ. Retrospective biodosimetry among United States radiologic technologists. *Radiat Res* 2007; 167: 727–734.
132. Krstev S, Ji BT, Shu XO, Blair A, Zheng W, Lubin JH, Vermeulen R, **Hauptmann M**, Rothman N, Gao YT, Mustafa D, Chow WH. Occupation and adult-onset asthma among Chinese women in a population-based cohort. *Am J Ind Med* 2007; 50: 265–273.
133. Van den Broeck GB, Balm AJM, Van den Brekel MWM, **Hauptmann M**, Schornagel JH, Rasch CRN. Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer. *Radiother Oncol* 2006; 81: 143–150.
134. Rajaraman P, Sigurdson AJ, Doody MM, Freedman DM, **Hauptmann M**, Alexander BH, Linet MS. Lung cancer incidence among U.S. radiologic technologists, 1983–1998. *Int J Cancer* 2006; 119: 2481–2486.
135. Zabel EW, Alexander BH, Mongin SJ, Doody MM, Sigurdson AJ, Linet MS, Freedman DM, **Hauptmann M**, Mabuchi K, Ron E. Thyroid cancer and employment as a radiologic technologist. *Int J Cancer* 2006; 119: 1940–1945.
136. Linet MS, **Hauptmann M**, Freedman DM, Alexander BH, Miller J, Sigurdson AJ, Doody MM. Interventional radiography and mortality risks in U.S. radiologic technologists. *Pediatr Radiol* 2006; 36:113–120.
137. Doody MM, Freedman DM, Alexander BH, **Hauptmann M**, Rao RS, Miller J, Mabuchi K, Ron E, Sigurdson AJ, Linet MS. Breast cancer incidence in U.S. radiologic technologists. *Cancer* 2006; 106: 2707–2715.
138. Simon SL, Weinstock RM, Doody MM, Neton J, Wenzel T, Stewart P, Mohan AK, Yoder C, Freedman M, **Hauptmann M**, Ron E, Bouville A, Feng A, Cardarelli J, Utterback D, Linet M. Estimating historical radiation doses to a cohort of U.S. radiologic technologists. *Radiat Res* 2006; 166: 174–192.
139. Linet MS, Freedman DM, Mohan AK, Doody MM, Ron E, Mabuchi K, Alexander BH, Sigurdson A, **Hauptmann M**. Incidence of hematopoietic malignancies in U.S. radiologic technologists. *Occup Environ Med* 2005; 62: 861–867.

140. Sigurdson AJ, **Hauptmann M**, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. *Mut Res* 2005; 586: 173–188.
141. Cogliano VJ, Grosse Y, Baan RA, Straif K, Secretan MB, Ghissassi FE, and the **Working Group for Volume 88**. Summary of IARC Monographs on Formaldehyde, 2-Butoxyethanol, and 1-tert-Butoxy-2-Propanol. *Environ Health Persp* 2005; 113: 1205–1208.
142. Peters A, von Klot S, Heier M, Trentinaglia I, Cyrus J, Hörmann A, **Hauptmann M**, Wichmann HE, Löwel H. Particulate air pollution and nonfatal cardiac events. Part I. Air pollution, personal activities, and onset of myocardial infarction in a case-crossover study. *Res Rep Health Eff Inst* 2005; 124: 1–66.
143. Yoshinaga S, **Hauptmann M**, Sigurdson AJ, Doody MM, Freedman DM, Alexander BH, Linet MS, Ron E, Mabuchi K. Non-melanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. *Int J Cancer* 2005; 115: 828–834.
144. **Hauptmann M**, Lubin JH, Hayes RB, Stewart P, Blair A. Mortality from solid cancers among industrial workers exposed to formaldehyde. *Am J Epidemiol* 2004; 159: 1117–1130.
145. Sigurdson AJ, **Hauptmann M**, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. *BMC Cancer* 2004; 4:9.
146. Travis LB, **Hauptmann M**, Gaul LK, Storm HH, Goldman MB, Nyberg U, Berger E, Janower ML, Hall P, Monson RR, Holm LE, Land CE, Schottenfeld D, Boice JD Jr, Andersson M. Site-specific cancer incidence and mortality after cerebral angiography with or without radioactive thorotrast. *Radiat Res* 2003; 160: 691–706.
147. **Hauptmann M**, Lubin JH, Hayes RB, Stewart P, Blair A. Mortality from lymphohematopoietic malignancies among workers employed in formaldehyde industries. *J Natl Cancer Inst* 2003; 95: 1615–1623.
148. Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, **Hauptmann M**, Mohan AK, Yoshinaga S, Hill DA, Tarone R, Mabuchi K, Ron E, Linet MS. Cancer incidence in the U.S. radiologic technologists Health Study, 1983–1998. *Cancer* 2003; 97: 3080–3089.
149. **Hauptmann M**, Mohan AK, Doody MM, Linet MS, Mabuchi K. Mortality from diseases of the circulatory system in U.S. radiologic technologists. *Am J Epidemiol* 2003; 157: 239–248.
150. Freedman DM, Sigurdson AJ, Rao RS, **Hauptmann M**, Alexander BH, Mohan AK, Doody MM, Linet MS. Risk of melanoma among radiologic technologists in the United States. *Int J Cancer* 2003; 103: 556–562.
151. Mohan AK, **Hauptmann M**, Freedman DM, Ron E, Matanoski GM, Lubin JH, Alexander BH, Boice JD, Doody MM, Linet MS. Cancer and other causes of mortality among radiologic technologists in the United States. *Int J Cancer* 2003; 103: 259–267.
152. Walcott FL, **Hauptmann M**, Duphorne CM, Pillow PC, Strom SS, Sigurdson AJ. A case-control study of dietary phytoestrogens and testicular cancer risk. *Nutr Cancer* 2002; 44: 44–51.
153. Mohan AK, **Hauptmann M**, Linet MS, Ron E, Lubin JH, Freedman DM, Alexander BH, Boice JD, Doody MM, Matanoski GM. Breast cancer mortality among radiologic technologists in the United States. *J Natl Cancer Inst* 2002; 94: 943–948.
154. **Hauptmann M**, Pohlabein H, Lubin JH, Jöckel KH, Ahrens W, Brüske-Hohlfeld I, Wichmann HE. The exposure-time-response-relationship between occupational asbestos exposure and lung cancer in two German case-control studies. *Am J Ind Med* 2002; 41: 89–97.

155. **Hauptmann M**, Berhane K, Langholz B, Lubin JH. Using splines to analyse latency in the Colorado Plateau uranium miners cohort. *J Epidemiol Biostat* 2001; 6: 417–424.
156. **Hauptmann M**, Wellmann J, Lubin JH, Rosenberg PS, Kreienbrock L. The analysis of exposure-time-response relationships using a spline weight function. *Biometrics* 2000; 56: 1105–1108.
157. **Hauptmann M**, Lubin JH, Rosenberg PS, Wellmann J, Kreienbrock L. The use of sliding time windows for the exploratory analysis of temporal effects of smoking histories on lung cancer risk. *Stat Med* 2000; 19: 2185–2194.

Submitted Articles

1. Byrnes G, **Hauptmann M**, Cardis E, Bernier MO, Blettner M, Dabin J, Engels H, Istad TS, Johansen C, Kaijser M, Kjaerheim K, Pearce MS, Journy N, Meulepas JM, Moissonnier M, Ronckers C, Thierry-Chef I, Le Cornet L, Jahnen A, Pokora R, Bosch de Basea M, Figuerola J, Maccia C, Nordenskjold1 A, Harbron RW, Lee C, Simon SL, Berrington de Gonzalez A, Schuz J, Kesminiene A. Solid cancers other than brain after exposure to radiation from computed tomography scans in children and adolescents: findings and general methodological considerations from the European EPI-CT study.
2. **Hauptmann M**, Byrnes G, Cardis E, Bernier MO, Blettner M, Dabin J, Engels H, Istad TS, Johansen C, Kaijser M, Kjaerheim K, Pearce MS, Journy N, Meulepas JM, Moissonnier M, Ronckers C, Thierry-Chef I, Le Cornet L, Jahnen A, Pokora R, Bosch de Basea M, Figuerola J, Maccia C, Nordenskjold1 A, Harbron RW, Lee C, Simon SL, Berrington de Gonzalez A, Schuz J, Kesminiene A. Brain cancer after radiation exposure from paediatric computed tomography scans in the pooled European EPI-CT cohort.
3. Nikolakis G, Kristandt K, **Hauptmann M**, Becker M, Zouboulis CC. Short-term intravenous clindamycin enhances the benefit of oral clindamycin-rifampicin treatment in hidradenitis suppurativa: A retrospective case-series.
4. Little MP, Wakeford R, Bouffler SD, **Hauptmann M**, Hamadad N, Kendall GM. Risk of cancer following low dose ionising radiation exposure in early life.
5. Nitz U, Gluz O, Kuemmel S, Christgen M, Aktas B, Luedtke-Heckenkamp K, Grischke E, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, **Hauptmann M**, Kates R, Graeser M, Wuerstlein R, Shak S, Baehner F, Kreipe H, Harbeck N. Early endocrine response and 21-Gene Expression Assay for therapy guidance in luminal early breast cancer.
6. Jaehn P, Andresen H, Bergholz A, Pagonas N, **Hauptmann M**, Neugebauer EA, Holmberg C, Ritter O, Sasko B. Spatial and time patterns of hospitalisation rates of myocardial infarction in a region in eastern Germany.
7. Kilsdonk E, Van Dulmen-den Broeder E, Van Leeuwen FE, Van den Heuvel-Eibrink MM, Loonen JJ, Van der Pal HJ, Bresters D, Versluys D, Rob Pieters, **Hauptmann M**, Jaspers M, Neggers S, Raphael M, Tissing WJ, Kremer LC, Ronckers CM, DCOG LATER Study Group. Late mortality in childhood cancer survivors according to pediatric cancer diagnosis and treatment era in the Dutch LATER Cohort.
8. Little MP, Patel A, Lee C, **Hauptmann M**, Berrington de Gonzalez A, Albert P. Impact of reverse causation mechanism on cancer risk estimates associated with radiation exposure from computerized tomography exposure: a simulation study modeled on brain tumor.
9. De Boo LW, Jozwiak K, Kok M, Joensuu H, Lanttia S, Opdam M, Van Steenis C, Brugman W, Kluin RJ, Nederlof PM, **Hauptmann M** (joint senior author), Linn SC. Adjuvant capecitabine-containing chemotherapy benefits both BRCA1-like and non-BRCA1-like early-stage TNBC patients in the FinXX trial.

10. Streefkerk N, Teepen JC, Feijen EA, Jozwiak K, Van der Pal HJ, Ronckers CM, De Vries AC, Van der Heiden-van Der Loo AC, Hollema N, Van den Berg M, Loonen J, Bresters D, Versluys AB, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink MM, Van Leeuwen FE, Van Santen HM, Hudson MM, Hawkins M, **Hauptmann M**, Yoneoka D, Korevaar JC, Tissing WJ, Kremer LC, on behalf of the Dutch LATER Study Group. The cumulative burden of clinically relevant outcomes in long-term childhood cancer survivors and implications for survivorship care: a Dutch LATER study.
11. Retel VP, Lindenberg M, Dackus GM, Jozwiak K, **Hauptmann M**, Van Harten WH, Siesling S, Linn SC. Cost-effectiveness analysis of tamoxifen versus aromatase inhibitors in pre-, peri-, and postmenopausal ER and HER2 positive breast cancer patients based on cancer registry data.

Letters

Meulepas JM, Ronckers CM, Smets AMJB, Nievelstein RAJ, Gradowska P, Lee C, Jahnen A, Van Straten M, De Wit MY, Zonnenberg B, Klein WM, Merks JH, Visser O, Van Leeuwen FE, Hauptmann M. Response to Wollschläger, Blettner, and Pokora. *J Natl Cancer Inst* 2019; 111(9): 1002–1003.

Wojcik A, Bouffler S, **Hauptmann M**, Rajaraman P. Reply to Comment on "Considerations on the use of the terms radiosensitivity and radiosusceptibility". *J Radiol Prot* 2019; 39(1): 313.

Wakeford R, Azizova T, Dörr W, Garnier-Laplace J, **Hauptmann M**, Ozasa K, Rajaraman P, Sakai K, Salomaa S, Sokolnikov M, Stram D, Sun Q, Wojcik A, Woloschak G, Bouffler S, Little M, Shore R, Walsh L, Grosche B, Kai M, Rühm W. Re: Kocher et al. (2018). The dose and dose-rate effectiveness factor (DDREF). *Health Phys* 2019; 116(1): 96–99.

De Boer M, **Hauptmann M**, De Jong D, Van Leeuwen FE, Rakhorst HA, Van der Hulst RR. Letter to the Editor: response to "Macrot textured breast implants with defined steps to minimize bacterial contamination around the device: experience in 42,000 implants." *Plast Reconstr Surg* 2018; 142(4): 590e–591e.

Portier CJ, Armstrong B, Baguley BC, Baur X, Beliaev I, Belle R, Belpoggi F, Biggeri A, Bosland MC, Bruzzi P, Budnik LT, Bugge MD, Burns K, Calaf GM, Carpenter DO, Carpenter HM, Lopez-Carrillo L, Clapp R, Cocco P, Comba P, Davis D, Demers PA, DeWitt J, Forastiere F, Freedman JH, Fritschi L, Gaus C, Gohlke JM, Goldberg M, Greiser E, Hansen J, Hardell L, **Hauptmann M**, Huang W, Huff J, James MO, Jameson CW, Kortenkamp A, Kopp-Schneider A, Kromhout H, Larramendy ML, Landrigan PJ, Lash LH, Leszczynski D, Lynch CF, Magnani C, Mandrioli D, Martin FL, Merler E, Michelozzi P, Miligi L, Miller AB, Mirabelli D, Mirer FE, Naidoo S, Perry MJ, Petronio MG, Pirastu R, Portier RJ, Ramos KS, Robertson LW, Roosli M, Ross MK, Roy D, Rusyn I, Saldiva P, Sass J, Savolainen K, Scheepers PT, Sergi C, Silbergeld EK, Smith MT, Stewart BW, Sutton P, Tateo F, Terracini B, Thielmann HW, Thomas DB, Vainio H, Vena JE, Vineis P, Weiderpass E, Weisenburger DD, Woodruff TJ, Yorifuji T, Yu IJ, Zambon P, Zeeb H, Zhou SF. Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). *J Epidemiol Community Health* 2016; pii: jech-2015-207005.

Beane Freeman LE, Blair A, Lubin JH, Stewart PA, Hayes RB, Hoover RN, **Hauptmann M**. Response to Tarone and McLaughlin: RE: Mortality from solid tumors in the updated NCI formaldehyde worker cohort. *Am J Ind Med* 2014; 57(4): 488–489.

Hauptmann M, Meulepas JM. Re: Radiation exposure from CT scans in childhood and subsequent risk of leukaemia. *Lancet* 2012; 380(9855): 1736.

Rasch CR, **Hauptmann M**, Balm AJ. Re: Intra-arterial chemotherapy for advanced head and neck cancer: is there a verdict? *Cancer* 2011; 117(4): 874.

Van der Pal HJ, Van Dalen EC, **Hauptmann M**, Kok WE, Caron HN, Van den Bos C, Oldenburger F, Koning CC, Van Leeuwen FE, Kremer LC. Response to “Rosenberg H. Re: Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.” *Arch Intern Med* 2011; 171(3): 264–265.

Hauptmann M, Richardson DB. Re: Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. *Stat Med* 2011; 30:198–199.

Hauptmann M, Ronckers CM. Re: A further plea for adherence to the principles underlying science in general and the epidemiologic enterprise in particular. *Int J Epidemiol* 2010; 39(6): 1677–1679.

Hauptmann M, Stewart PA, Lubin JH, Beane Freeman LE, Hornung RW, Herrick RF, Hoover RN, Fraumeni Jr JF, Blair A, Hayes RB. Response to “Cole P, Adami HO, Trichopoulos D, Mandel J. Re: Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde.” *J Natl Cancer Inst* 2010; 102(19): 1519–1520.

Lodder WL, **Hauptmann M**, Teertstra HJ, Van den Brekel MW, Balm AJ. Re: Is preoperative ultrasonography accurate in measuring tumor thickness and predicting the incidence of cervical metastasis in oral cancer? *Oral Oncol* 2010; 46(8): 627.

Zhang L, Ji Z, Guo W, Hubbard AE, Galvan N, Xin KX, Azuma M, Smith MT, Tang X, Qiu C, Ge Y, Hua M, Ruan X, Li S, Xie Y, Li L, Huang H, Rothman N, Shen M, Beane Freeman L, Blair A, Alter BP, Moore LE, Hayes RB, **Hauptmann M**, Stewart P, Fraumeni Jr JF, Lan Q, Vermeulen R, Reiss B, Liu S, Xiong J, Kim S, Rappaport SM. Response to “Speit G, Gelbke HP, Pallapies D, Morfeld P. Occupational exposure to formaldehyde, hematotoxicity and leukemia-specific chromosome changes in cultured myeloid progenitor cells – Letter.” *Cancer Epidemiol Biomarkers Prev* 2010; 19: 1884–1885.

Hauptmann M, Lubin JH, Hayes RB, Stewart P, Blair A. Response to “Tarone RE, McLaughlin JK. Re: Mortality from Solid Cancers among Workers in Formaldehyde Industries.” *Am J Epidemiol* 2005; 161: 1089–1091.

Hauptmann M, Lubin JH, Hayes RB, Stewart P, Blair A. Response to “Casanova M, Cole P, Collins JJ, Conolly R, Delzell E, Heck HA, Leonard R, Lewis R, Marsh GM, Ott MG, Sorahan T, Axten CW. Re: Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries.” *J Natl Cancer Inst* 2004; 96: 967–968.

Hauptmann M, Sigurdson AJ, Rutter JL, Chatterjee N, Hill DA, Doody MM, Struewing JP. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. *J Natl Cancer Inst* 2003; 95: 1251–1252.

Books and Book Chapters

Hauptmann M, Straif K, Pesch B. Formaldehyd [Formaldehyde]. In: Wichmann HE, Schlipkötter HW, Fülgraff G, editors. *Handbuch der Umweltmedizin [Handbook of Environmental Medicine]*. Ecomed Verlag, Landsberg, 2006. In German.

Hauptmann M. *Analysis of exposure-time-response relationships using a spline weight function and its application in epidemiology*. Dissertation. Roderer Verlag, Regensburg, 1999.

Invited Presentations

Radiation exposure from pediatric CT scans and cancer risk. Seminar for the German Commission on Radiological Protection (SSK), an advisory body of the Federal Ministry for the Environment, Nature Conservation and Nuclear Safety. Bonn, Germany (2019).

Radiation exposure from pediatric CT scans and cancer risk. Exchange seminar of members of the International Commission of Radiological Protection (ICRP) with young scientists of the Radiation Effects Research Foundation (RERF), RERF. Hiroshima, Japan (2018).

Genetic susceptibility to radiation induced breast cancer after Hodgkin Lymphoma. Workshop of the International Commission of Radiological Protection (ICRP), the National Institutes for Quantum and Radiological Science and Technology (QST), and the Radiation Effects Research Foundation (RERF) on Individual Response to Ionising Radiation, National Cancer Center Japan. Tokyo, Japan (2018).

Introduction to the EPI-CT study: overall design and methods. 23st Conference on Radiation & Health and 64th Annual International Meeting of the Radiation Research Society. Chicago, U.S.A. (2018).

Brain cancer risk after radiation exposure from pediatric CT scans in the EPI-CT study. 23st Conference on Radiation & Health and 64th Annual International Meeting of the Radiation Research Society. Chicago, U.S.A. (2018).

Confounding and selection bias in epidemiologic studies of low-dose radiation. 23st Conference on Radiation & Health and 64th Annual International Meeting of the Radiation Research Society. Chicago, U.S.A. (2018).

Medical radiation exposure – from diagnostic to therapeutic (Keynote presentation). 5th European Congress of the International Radiation Protection Association. The Hague, The Netherlands (2018).

Review of studies on medical radiation exposure. International Conference on Radiation Biology. Chennai, India (2016).

Statistical methods in radiation epidemiology. Workshop on risk of secondary cancer following radiotherapy. Organized by Stockholm University, Karolinska Institute and the Royal Swedish Academy of Sciences. Stockholm, Sweden (2016).

The Dutch Pediatric CT Study on radiation exposure from pediatric computed tomography and cancer risk. European Radiation Research Conference. Amsterdam, The Netherlands (2016).

Pre- and post-pregnancy cigarette smoking and the risk of premenopausal breast cancer. 10th European Breast Cancer Conference. Amsterdam, The Netherlands (2016).

EPI-CT – Statistical challenges in a European study of radiation exposure from pediatric CTs and cancer risk. DoReMi LD-RadStats: Workshop for statisticians interested in contributing to EU low dose radiation research. Barcelona, Spain (2015).

Second malignancies among adolescents following radiotherapy. 11th Quinquennial Conference of the Dutch Association for Radiation Hygiene. Leiden, Netherlands (2015).

Potential confounding in studies of radiation exposure from pediatric CT scans and cancer. 21st Conference on Radiation & Health and 60th Annual International Meeting of the Radiation Research Society. Las Vegas, U.S.A. (2014).

What to expect from ongoing European studies of CT-related cancer risks. Annual Meeting of the British Association for Radiation Research. Brighton, UK (2014).

Statistical models for latency analyses of protracted exposures. 4th International Conference on Risk Analysis. Limassol, Cyprus (2011).

Risk prediction models vs. individual biomarkers: an example. Workshop “Modeling risk prediction”. Banff International Research Station, Banff, Canada (2009).

Updates of two NCI studies: the formaldehyde cohort & a case-control study of embalmers – description and comparison. International Formaldehyde Science Conference, Barcelona, Spain (2007).

Statistical methods for assessing latency in epidemiologic studies. Annual meeting of the Research Training Group “Statistical Modeling”, Department of Statistics, University of Dortmund, Germany. Witten, Germany (2006).

Missing exposure history and other methodologic issues in occupational cohort studies. Workshop on the future needs for epidemiologic studies of extremely low frequency magnetic fields in the electric utility industry. Edinburgh, United Kingdom (2006).

NCI cohort among workers in formaldehyde industries. Annual European Meeting of The Toxicology Forum, Brussels, Belgium (2005).

Formaldehyde and cancer – recent epidemiologic results and their interpretation. Federal Institute for Risk Assessment, Berlin, Germany (2005).

Formaldehyde and cancer – recent epidemiologic results and their interpretation. German Cancer Research Center, Heidelberg, Germany (2005).

Formaldehyde and cancer – recent epidemiologic results and their interpretation. Netherlands Cancer Institute, Amsterdam, The Netherlands (2005).

Statistical methods for assessing latency in epidemiologic studies. Netherlands Cancer Institute, Amsterdam, The Netherlands (2004).

Epidemiologic studies of formaldehyde and cancer – recent results and their interpretation. 17th International Symposium on Epidemiology in Occupational Health, Melbourne, Australia (2004).

Cancer mortality among industrial workers exposed to formaldehyde. Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, U.S.A. (2004).

Updated analysis of the NCI industry-wide study of workers exposed to formaldehyde. The Toxicology Forum Winter Meeting, Washington, D.C., U.S.A. (2004).

Cancer mortality among industrial workers exposed to formaldehyde. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, U.S.A. (2003).

Mortality from diseases of the circulatory system in U.S. radiologic technologists. Radiation Epidemiology Branch, National Cancer Institute, Bethesda, Maryland, U.S.A. (2002).

The U.S. radiologic technologists cohort: results from the analysis of mortality from diseases of the circulatory system, and design and approaches for studies of the genetic components of breast cancer. Institute of Epidemiology, GSF National Research Center for Environment and Health, Neuherberg, Germany (2002).

Statistical issues for the analysis of case-crossover data on myocardial infarction and air pollution. Workshop on the German Case-Crossover Study on Myocardial Infarction and Air Pollution, Seattle, Washington, U.S.A. (2002).

Regression splines and their application in epidemiology. Biometric Program, Department of Animal and Avian Sciences, University of Maryland, College Park, Maryland, U.S.A. (2002).

On the exposure-time-response relationship between occupational asbestos exposure and lung cancer in two German case-control studies. Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen, Germany (2000).

On the exposure-time-response relationship between occupational asbestos exposure and lung cancer in two German case-control studies. Biostatistics Branch, National Cancer Institute, Bethesda, Maryland, U.S.A. (2000).

Exposure-time-response analysis of chronic exposures like indoor radon. Workshop on Mechanistic Models for Radon Carcinogenesis, Neuherberg, Germany (1999).

Risk modeling of individual exposure profiles in epidemiology. Department of Statistics, University of Dortmund, Germany (1997).

Teaching Record

PhD student Johanna Meulepas “Leukemia after radiation exposure from pediatric computed tomography” (2018).

Faculty for 1-week CONCERT training course “Uncertainty analysis for low dose radiation research”. Barcelona, Spain (2016, 2017).

Organizer and instructor of 1-week course “Basic medical statistics for clinical and experimental research”. Netherlands Cancer Institute, Amsterdam, The Netherlands (annually 2010–2018).

Population-based genetic epidemiology. Two-day short course. School of Medicine, University of Munich, Germany (annually 2002–2017).

Faculty for short course “Cancer epidemiology”. Netherlands Institute for Health Sciences, Erasmus University, Rotterdam, The Netherlands (bi-annually 2010–2019).

Faculty for 3-week DoReMi training course “Radiation Epidemiology and Dosimetry”. Helmholtz Zentrum München, Germany (2014).

Gene-environment interactions in case-control designs. Lecture. Department of Epidemiology and Preventive Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, U.S.A. (2004).

Creating person-years tables using EPICURE software. Tutorial. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, U.S.A. (2002).

Grants

Ongoing

Dutch Cancer Society. Role: Co-PI. A risk prediction tool for cardiovascular disease in breast cancer patients, 2017–2020. Total award: EUR 437,130.

Netherlands Cancer Institute Infrastructure Award. Role: PI. Innovative design and statistical analysis of animal studies at the Netherlands Cancer Institute, 2017–2018. Total award: EUR 81,000.

Dutch Cancer Society. Role: PI. Novel statistical methods for efficient identification of biomarkers for personalized cancer treatment, 2017–2021. Total award: EUR 400,300.

Dutch Cancer Society. Role: PI. Statistical assessment of cancer risks from therapeutic radiation exposure incorporating the spatial distribution of radiation dose in the target organ, 2017–2021. Total award: EUR 440,555.

European Commission. Role: Co-Investigator. PI: Cardis E. MEDIRAD – Implications of medical low dose radiation exposure, 2017–2021. EC grant number 755523, Horizon 2020. Total award: EUR 10,000,000. Own share: EUR 186,875.

Dutch Cancer Society. Role: Co-Investigator. PI: Beets-Tan R, Lambregts D. A multiparametric imaging model for pre-treatment prediction of treatment response in rectal cancer, 2017–2021. Total award: EUR 472,397. Own share: EUR 16,000.

Dutch Cancer Society. Role: Co-Investigator. PI: Schmidt M, Hooning M, Steyerberg E. Risk management of contralateral breast cancer: development and validation of an online decision aid for physicians and patients, 2014–2019. Total award: EUR 1,193,720. Own share: EUR 35,000.

The Netherlands Organisation for Health Research and Development (ZonMw). Role: Co-Investigator. PI: Linn S, Rodenhuis S. The Netherlands Breast Cancer Project (NBCP): Towards personalized medicine by using the nationwide population-based breast cancer registry (1989-2011) coupled with biobanking, 2012–2018. Total award: EUR 320,321. Own share: EUR 14,914.

Dutch Cancer Society. Role: Co-Investigator. PI: Schagen S, Ikram A, Stricker B. Trajectories of cognitive decline in survivors of non-CNS cancers: from precancer diagnosis to late life after cancer, 2016–2020. Total award: EUR 435,762. Own share: EUR 21,000.

Dutch Cancer Society. Role: Co-Investigator. PI: Boekhout AH, Aaronson NK, Van Weert HC. A randomized study, PROstate cancer follow-up care in Secondary and Primary hEalth Care (PROSPEC), 2015–2019. Total award: EUR 571,910. Own share: EUR 15,930.

KIKA Foundation. Role: Co-Investigator. PI: Ronckers CM, Kremer L, Van der Pal H, Neggers S, Janssens G. Radiotherapy-related meningioma, cerebrovascular events, and cataract in childhood cancer survivors: A DCOG LATER Study project, 2015–2019. Total award: EUR 490,000. Own share: EUR 7,000.

Completed

European Commission. Role: Work package leader. EPI-CT – Epidemiological study to quantify risks for pediatric computerized tomography and to optimize doses, 2011–2017. EC grant number 269912, FP7-Fission-2010. Total award: EUR 3,000,000. Own share: EUR 307,588.

Worldwide Cancer Research. Role: Principal Investigator. Leukaemia after radiation exposure from paediatric computed tomography, 2012–2016. Total award: EUR 296,000.

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. Radiation dose-response and second primary cancers of stomach, esophagus and pancreas: a study of cancer survivors, 2003. Total award: USD 2,385,791.

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. Scientific conference on “Pediatric CT scanning and risk for childhood cancer: International Collaborative Study”, 2006 (Total award: USD 25,000)

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. Cancer risk following radiation exposure from computed tomography in children and adolescents, 2005 (Total award: USD 1,000,000)

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. Fluorescence in situ hybridization (FISH) chromosomal aberration analysis among U.S. radiologic technologists, 2003–2004 (Total award: USD 244,000)

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. U.S. Radiologic Technologists Cohort: New strategies for follow-up and detailed study of radiation, genetic factors, and risk of cancer and benign high risk conditions, 2003–2008 (Total award: USD 2,249,338)

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. DNA repair phenotype and genotype in early-onset breast, multiple primary, and thyroid cancers among U.S. radiologic technologists, 2002–2003 (Total award: USD 56,250)

National Cancer Institute, National Institutes of Health (Intramural Program). Role: Co-Investigator. A prospective cohort study of occupational exposures and cancer risks among men in Shanghai, China, 2000–2004 (Total award: USD 3,666,992)

Professional Service

Reviewer of manuscripts for N Engl J Med, JAMA, J Clin Oncol, J Natl Cancer Inst, Lancet Oncol, Br J Cancer, Stat Med, Biometrics, Biom J, Radiat Res, Gastroenterology, Ann Onc, Am J Epidemiol, Epidemiology, Cancer Epidemiol Biomarkers Prev, Lancet Regional Health Europe, Risk Analysis, BMC Cancer, Breast Cancer Res, Cancer Causes Control, J Radiol Prot, Cancer Epidemiol, Cancer Lett, Cancer Res, Clin Cancer Res, Environ Int, Environ Health Perspect, Indoor Air, Int J Cancer, Int J Epidemiol, Int J Radiat Biol, Int J Radiat Oncol Biol Phys, J Epidemiol Biostat, J Radiat Res, Eur Arch Otorhinolaryngol, Radiat Environ Bioph, PLOS ONE

Reviewer of grant proposals

- European Commission (7th Framework Programme, 2012/2013 Work Programme, area “Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer”)
- European Commission (7th Framework Programme, 2011 Work Programme, area “Clinical trials in rare cancers”)
- The Netherlands Organisation for Health Research and Development (ZonMw, Vici)
- Foundation Children Cancerfree (Stichting Kinderen Kankervrij)
- Deutsche Forschungsgemeinschaft
- French National Research Agency
- Research Secretariat of the Workers’ Compensation Board of British Columbia (WorkSafeBC)
- Government of Alberta (Canada), Occupational Health and Safety Research Funding Program

Full member, Task Group 111 “Factors governing the individual response of humans to ionising radiation”, International Commission on Radiological Protection (2018–2022)

Organizer, Workshop “Absolute risk prediction” by Mitchell H. Gail and Ruth Pfeiffer (US National Cancer Institute), October 18, 2012, Netherlands Cancer Institute, Amsterdam, Netherlands

Organizer and Chair, International mini-symposium “Radiation exposure from computed tomography scans and cancer risk”, July 15, 2011, Netherlands Cancer Institute, Amsterdam, Netherlands

Co-organizer, Scientific conference “Pediatric CT scanning and risk for childhood cancer: International Collaborative Study”, Lyon, France (March 2006)

Organizer and Chair, Mini-symposium “Formaldehyde & cancer: Current evidence and future perspectives” at the 17th International Symposium on Epidemiology in Occupational Health, Melbourne, Australia (October 2004)

Member, Organizing Committee, Workshop on Mechanistic Models for Radon Carcinogenesis, Neuherberg, Germany (March 1999)